Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Cancer J. 2011 Sep;17(5):359–371. doi: 10.1097/PPO.0b013e3182325e63

Figure 1. Overall survival advantage using PROSTVAC.

Figure 1

Overall survival of a randomized, placebo (empty vector) controlled 43-center trial of PROSTVAC (rV-, rF-PSA-TRICOM) vaccine in patients with metastatic castrate-resistant prostate cancer (mCRPC). There was an overall survival advantage of 8.5 months (p=0.006) and a 44% reduction in death in the vaccine arm. Adapted from Kantoff, et al.57